Hakim Bouterfa

2.9k citations

40 papers · 2.4k indexed · h-index 23

Impact in

Neurology top 2%
- Neuroblastoma Research and Treatments
Oncology top 2%
- Lung Cancer Research Studies

Papers in ⓘ

Neurology 13
- Neuroblastoma Research and Treatments 12
Oncology 15
- Lung Cancer Research Studies 12

Co-authors: K. Roosen (10 shared papers)Detlef Doenecke (7 shared papers)François Jamar (4 shared papers)Larry K. Kvols (4 shared papers)Raffaella Barone (4 shared papers)Roelf Valkema (3 shared papers)Eric P. Krenning (2 shared papers)Jens Kaufmann (6 shared papers)
Journals: Journal of Nuclear Medicine (3 papers)European Journal of Biochemistry (2 papers)Neurosurgery (2 papers)Journal of Neuro-Oncology (2 papers)European Journal of Nuclear Medicine and Molecular Imaging (2 papers)
Partner nations: Germany United States Switzerland

In The Last Decade

Hakim Bouterfa

40 papers receiving 2.3k citations

Peers

Countries citing papers authored by Hakim Bouterfa

Since Specialization

Citations

This map shows the geographic impact of Hakim Bouterfa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hakim Bouterfa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hakim Bouterfa more than expected).

Fields of papers citing papers by Hakim Bouterfa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hakim Bouterfa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hakim Bouterfa. The network helps show where Hakim Bouterfa may publish in the future.

Co-authors

The 25 scholars most cited alongside Hakim Bouterfa, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hakim Bouterfa Line = papers co-authored together Hakim Bouterfa links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors Seminars in Nuclear Medicine ·Roelf Valkema, Stanislas Pauwels, Larry K. Kvols, Raffaella Barone, François Jamar, Willem H. Bakker, Dik J. Kwekkeboom, Hakim Bouterfa, Eric P. Krenning	2006	234
2	⁹⁰Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide Journal of Clinical Oncology ·David Bushnell, Thomas M. O’Dorisio, M. Sue O’Dorisio, Yusuf Menda, Rodney J. Hicks, Eric Van Cutsem, J.-L. Baulieu, Françoise Borson‐Chazot, Lowell Anthony, Al B. Benson, Kjell Öberg, Ashley Grossman, Mary Connolly, Hakim Bouterfa, Yong Li, Katherine Kacena, Norman LaFrance, Stanislas Pauwels	2010	225
3	86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion European Journal of Nuclear Medicine and Molecular Imaging ·François Jamar, Raffaella Barone, Isabelle Mathieu, Stéphan Walrand, Daniel Labar, Pascal Carlier, J Camps, Horst Schran, Tianling Chen, Malcolm C. Smith, Hakim Bouterfa, Roelf Valkema, Eric P. Krenning, Larry K. Kvols, Stanislas Pauwels	2003	177
4	A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR^® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegaly Clinical Endocrinology ·Moisés Mercado, Fátima Borges, Hakim Bouterfa, Tien‐Chun Chang, Alberto Chervín, Andrew J. Farrall, Attila Patócs, Stephan Petersenn, J Podoba, M Safari, Joanna M. Wardlaw, (unknown)	2007	158
5	Sensitivity Comparison of ⁶⁸Ga-OPS202 and ⁶⁸Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study Journal of Nuclear Medicine ·Guillaume Nicolas, N. Schreiter, Felix Kaul, John Uiters, Hakim Bouterfa, Jens Kaufmann, Tobias E. Erlanger, Richard Cathomas, Emanuel Christ, Melpomeni Fani, Damian Wild	2017	129
6	Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomasIn vitro International Journal of Cancer ·Joerg‐Christian Tonn, Siglinde Kerkau, Anne Hanke, Hakim Bouterfa, Justus G. Mueller, Sven Wagner, Giles H. Vince, K. Roosen	1999	126
7	Biodistribution, Pharmacokinetics, and Dosimetry of ¹⁷⁷Lu-, ⁹⁰Y-, and ¹¹¹In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist ¹⁷⁷Lu-DOTATATE: The Mass Effect Journal of Nuclear Medicine ·Guillaume Nicolas, Rosalba Mansi, Lisa McDougall, Jens Kaufmann, Hakim Bouterfa, Damian Wild, Melpomeni Fani	2017	112
8	Inhibition of Ras farnesylation by lovastatin leads to downregulation of proliferation and migration in primary cultured human glioblastoma cells. PubMed ·Hakim Bouterfa, V Sattelmeyer, Stefanie Czub, Dirk Vordermark, K. Roosen, Joerg-Christian Tonn	2000	112
9	Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours European Journal of Nuclear Medicine and Molecular Imaging ·Andreas Helisch, GregorJ. F�rster, Helmut Reber, Hans‐Georg Buchholz, Rudolf Arnold, B. G�ke, MatthiasM. Weber, Bertram Wiedenmann, Stanislas Pauwels, Ulrike Haus, Hakim Bouterfa, Peter Bartenstein	2004	102
10	Long‐Acting Octreotide and Prolonged‐Release Lanreotide Formulations Have Different Pharmacokinetic Profiles The Journal of Clinical Pharmacology ·B Astruc, Peter Marbach, Hakim Bouterfa, Caroline Denot, M Safari, Alessandra Vitaliti, Michael C. Sheppard	2005	102
11	Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open‐label, multicentre study Clinical Endocrinology ·Annamaria Colao, Paolo Cappabianca, Philippe Caron, Ernesto De Menis, Andrew J. Farrall, Mônica R. Gadelha, Abdel Hmissi, Aled Rees, Martín Reincke, M Safari, Guy T’Sjoen, Hakim Bouterfa, Ross C. Cuneo	2008	86
12	Early increase in histone H1(0) mRNA during differentiation of F9 cells to parietal endoderm. The EMBO Journal ·A. Alonso, B. Breuer, Hakim Bouterfa, Detlef Doenecke	1988	81
13	Organization and expression of H1 histone and H1 replacement histone genes Journal of Cellular Biochemistry ·Detlef Doenecke, Werner Albig, Hakim Bouterfa, Birgit Drabent	1994	76
14	Retinoids Inhibit Human Glioma Cell Proliferation and Migration in Primary Cell Cultures But Not in Established Cell Lines Neurosurgery ·Hakim Bouterfa, Thomas Picht, Daniel Ke, Christian Herbold, Elizabeth Noll, Peter McL. Black, K. Roosen, J. C. Tonn	2000	73
15	Safety, Biodistribution, and Radiation Dosimetry of ⁶⁸Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study Journal of Nuclear Medicine ·Guillaume Nicolas, Seval Beykan, Hakim Bouterfa, Jens Kaufmann, Andreas Bauman, Michael Laßmann, Jean Claude Reubi, Jean Rivier, Helmut R. Maëcke, Melpomeni Fani, Damian Wild	2017	68
16	Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. PubMed ·David Bushnell, Thomas M. O’Dorisio, Yusuf Menda, Thomas Carlisle, Pamela Zehr, Mary Connolly, Mark Karwal, Sara Miller, Stan Parker, Hakim Bouterfa	2003	53
17	Expression of Different Extracellular Matrix Components in Human Brain Tumor and Melanoma Cells in Respect to Variant Culture Conditions Journal of Neuro-Oncology ·Hakim Bouterfa, Anne-Rose Darlapp, Eberhardt Klein, Torsten Pietsch, K. Roosen, Jörg C. Tonn	1999	43
18	Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues Nephrology Dialysis Transplantation ·Raffaella Barone, Stanislas Pauwels, J Camps, E. P. Krenning, Larry K. Kvols, Mark Caleb Smith, Hakim Bouterfa, Olivier Devuyst, François Jamar	2004	42
19	Isolation of two murine H1 histone genes and chromosomal mapping of the H1 gene complement Mammalian Genome ·Birgit Drabent, K. Franke, Christa Bode, U. Kosciessa, Hakim Bouterfa, H. Hameister, Detlef Doenecke	1995	41
20	Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons. PubMed ·Andrea Fanjul, Hakim Bouterfa, Marcia I. Dawson, Magnus Pfahl	1996	40

About Hakim Bouterfa

Hakim Bouterfa is a scholar working on Neurology, Oncology, Epidemiology, Immunology and Allergy and Biochemistry, having authored 40 papers that have together received 2.4k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (18 papers), Lung Cancer Research Studies (12 papers), Neuroblastoma Research and Treatments (12 papers), Retinoids in leukemia and cellular processes (4 papers), Growth Hormone and Insulin-like Growth Factors (4 papers), Estrogen and related hormone effects (4 papers), Cell Adhesion Molecules Research (3 papers) and Genomics and Chromatin Dynamics (3 papers). The work is most often cited by research in Neurology (709 citations), Oncology (1.0k citations), Epidemiology (1.1k citations), Endocrinology, Diabetes and Metabolism (373 citations) and Radiology, Nuclear Medicine and Imaging (491 citations). Hakim Bouterfa has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include K. Roosen, Detlef Doenecke, François Jamar, Larry K. Kvols, Raffaella Barone, Roelf Valkema, Eric P. Krenning, Jens Kaufmann, Damian Wild and Melpomeni Fani. Their work appears in journals such as Journal of Nuclear Medicine, European Journal of Biochemistry, Neurosurgery, Journal of Neuro-Oncology and European Journal of Nuclear Medicine and Molecular Imaging.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact